Scrub typhus is a public health concern for a population of over a billion humans, with an estimated incidence of one million cases/year in endemic areas. Although doxycycline remains the standard therapy, fluoroquinolones have been used successfully in a few patients. However, there is also clinical evidence that fluoroquinolones are ineffective in the treatment of scrub typhus. To clarify this matter, we determined the in vitro susceptibility of Orientia tsutsugamushi strain Kato to ciprofloxacin and sequenced the quinolone resistance-determining region (QRDR) of the gyrA gene, the target of fluoroquinolones, of 18 fresh isolates from Lao PDR.
M a n u s c r i p t
Introduction
Orientia tsutsugamushi, the agent of scrub typhus, is a small Gram-negative obligate intracellular bacterium of the alpha subgroup of Proteobacteria, transmitted to humans by the bite of trombiculid mites. The disease is a public health concern for a population of over a billion humans in a geographical triangle extending from northern Japan and far eastern Russia in the north, to northern Australia in the south and Pakistan and Afghanistan in the west [1] [2] [3] . The estimated incidence of the disease in endemic areas is one million cases/year. Although doxycycline and chloramphenicol remain the gold standard therapy for scrub typhus, ciprofloxacin has been shown to be effective in a mouse model [4] and in some anecdotal clinical cases [5] [6] [7] . However, recent reports of clinical failure and deaths as well as abortions in pregnant women with fluoroquinolone therapy suggest drug resistance in these cases [8] [9] [10] . Fluoroquinolone activity is due to inhibition of bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. It has been demonstrated that resistance to quinolones in intracellular bacteria was mainly due to point mutations in the quinolone resistance-determining region (QRDR) of DNA gyrase (gyrA) [11, 12] .
Surprisingly, there are only a few reports regarding in vitro and/or in vivo antibiotic susceptibility in cell culture or animal models of O. tsutsugamushi, especially for fluoroquinolones. In the in vitro work of Kelly et al. [13] , although they determined precisely the doxycycline minimum inhibitory concentration (MIC) against O.
tsutsugamushi Karp strain, they tested only one high concentration of ciprofloxacin (4 g/mL) that was found to be effective in vitro. Similarly, McLain et al. [4] found that ciprofloxacin was effective in preventing death in a mouse model of scrub typhus, but the appropriateness of such a mouse model to human disease is uncertain and the tsutsugamushi strain Kato using a modified real-time quantitative polymerase chain reaction (qPCR) assay previously used for Rickettsia spp. and Coxiella burnetii [14, 15] ; (ii) to amplify and sequence the gyrA gene of recent human O.
tsutsugamushi isolates from Lao PDR (Laos); and (iii) to compare these sequences with those retrieved from available full sequenced genomes of strains Boryong [16] and Ikeda [17] in order to decipher the possible molecular mechanism of resistance to fluoroquinolones.
Materials and methods

Patients and rickettsial culture
Patients were recruited to a study of the causes of fever [1] . Buffy coats, prepared M a n u s c r i p t 6
Preparation of Orientia tsutsugamushi inocula
Orientia tsutsugamushi strain Kato (CSUR R163) was propagated in monolayers of L929 cells grown in minimum essential media (MEM) supplemented with 5% fetal bovine serum (FBS) and 2 mM L-glutamine (Invitrogen, Cergy-Pontoise, France).
When almost 100% of the floating cells were infected, as determined by Giemsa (Merck, Darmstadt, Germany) staining, cells were harvested, disrupted by glass beads (diameter 3 mm) and centrifuged at 500  g for 5 min at 4 C. The supernatant containing O. tsutsugamushi was centrifuged again at 2000  g for 10 min at 4 C to collect the bacterial pellet. Orientia tsutsugamushi was cryopreserved in MEM containing 20% FBS and 5% dimethyl sulphoxide (DMSO) and stored at -80 C until use. The infectivity titre of inocula was determined as described previously [19] with slight modification. Briefly, the inoculum was five-fold serially diluted and inoculated onto L929 cells grown in a 24-well plate. After 2 h of inoculation, the inoculum was removed and replaced by new media containing 0.4 g/mL daunorubicin (BIOMOL, Lausen, Switzerland), which partially inhibits the growth of host cells [20] . After 2 days of incubation, cells were collected and stained by indirect immunofluorescence assay using pooled human sera from Thai patients [2] with scrub typhus at a dilution A c c e p t e d M a n u s c r i p t 7
Antibiotic susceptibility testing
Growth of intracellular O. tsutsugamushi in cell culture with different concentrations of antibiotics was determined using real-time PCR with a TaqMan ® probe as previously described for Rickettsia [15] . 
Determination of the quinolone resistance-determining region of gyrA and protein sequences alignment
Eighteen strains of O. tsutsugamushi isolated from the blood of Lao patients with scrub typhus [1] were used for determination of the QRDR sequence of gyrA. DNA was extracted from the blood sample (buffy coat layer) using a QIAamp DNA Mini Kit 
Results and discussion
In the real-time qPCR assay, the MIC determined in duplicate against ciprofloxacin and ofloxacin for O. tsutsugamushi strain Kato was 8 g/mL (Fig. 1 ). Experiments were carried out twice to confirm the results. Compared with E. coli, the QRDR region of gyrA of the 18 Lao O. tsutsugamushi isolates as well as those retrieved M a n u s c r i p t 9 from the KEGG website (strains Boryong and Ikeda) displayed an intrinsic Ser83Leu mutation (Fig. 2) . Moreover, 19 of the 20 sequences had a Thr88Ser mutation, 1 isolate had a Thr88Ala mutation and all 20 protein sequences had an Ile89Leu mutation. Thus, looking at in vitro and in silico results, it was found that O.
tsutsugamushi strain Kato was intrinsically resistant to ciprofloxacin and that all available sequences of the O. tsutsugamushi QRDR domain of gyrA had an intrinsic mutation at position 83 known to be associated with fluoroquinolone resistance, as has been established in other intracellular bacteria including Ehrlichia spp., Bartonella spp. and Tropheryma whipplei [11, 12] . Therefore, these data provide evidence that O. tsutsugamushi is naturally resistant to fluoroquinolones, explaining clinical failures reported using such antibiotics in the treatment of scrub typhus.
Indeed, there are several reports demonstrating that ciprofloxacin is not effective in the treatment of scrub typhus (Table 1) . In an outbreak in Southern India, among 28 patients serologically confirmed to have scrub typhus, 17 patients treated with doxycycline and 2 patients treated with chloramphenicol recovered in 1-3 days [9] .
However, in five patients who received ciprofloxacin, fever subsided only after 5 days. Three patients (10.7%) died, including one patient treated with doxycycline and two with fluoroquinolones, indicating a possibility of drug resistance [9] . Similarly, we have reported five pregnant Indian patients with scrub typhus, four of whom were treated initially with ciprofloxacin [8] . Three women had stillbirths, one an abortion and one a low birth weight baby [8] . Scrub typhus has also been transmitted by needle stick from a patient who received pefloxacin [21] . Finally, Tsai et al. [10] have
shown recently in a retrospective case series of 132 patients with scrub typhus that although treatment with levofloxacin was effective in 71 patients, the patients had a significantly longer time to defervescence compared with 61 patients treated with M a n u s c r i p t 10 tetracyclines. Moreover, for patients with severe scrub typhus, higher mortality was observed in the levofloxacin-treated group [10] . There are three reports of apparent successful scrub typhus therapy with fluoroquinolones [5, 6, 22] , although the evidence for scrub typhus as the aetiology of the disease is uncertain for one patient [5] . Our in vitro and in silico findings re-emphasise the usefulness of such analysis for prediction of antibiotic resistance in intracellular bacteria. These results suggest that fluoroquinolones should not be used for the treatment of scrub typhus. M a n u s c r i p t
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